Baxter International Inc. (NYSE:BAX), a global leader in injectables, anesthesia, and drug compounding, has announced the expansion of its Pharmaceuticals portfolio in the U.S. with the launch of five new injectable products.
Alok Sonig, Executive Vice President and Group President of Pharmaceuticals at Baxter, stated, “These launches reflect Baxter’s commitment to offering innovative products that address unmet patient needs in critical therapeutic areas such as anti-infectives and anti-hypotensives. We are pleased to introduce these important new options to our customers and are dedicated to bringing further innovations to the market.”
The newly launched products in Baxter’s Pharmaceuticals portfolio in the U.S. include:
- Norepinephrine Bitartrate in 5% Dextrose Injection in a new 16 mg/250 mL strength, indicated for raising blood pressure in adult patients with severe, acute hypotension.
- Vasopressin in 0.9% Sodium Chloride Injection, the first FDA-approved ready-to-use Vasopressin in a flexible container, indicated for increasing blood pressure in adults with vasodilatory shock.
- Vancomycin Injection, USP in 5% Dextrose in new 1.25 g/250 mL and 1.5 g/300 mL strengths, the first frozen ready-to-use offerings in 250 mL and 300 mL volumes, indicated for serious infections caused by susceptible strains of methicillin-resistant staphylococci.
- Ropivacaine Hydrochloride Injection, USP in a ready-to-use, single-dose infusion bag, indicated for producing local or regional anesthesia for surgery and acute pain management.
- Regadenoson Injection pre-filled syringe, a coronary vasodilator used in pharmacologic stress testing.
These new products, available in ready-to-use formats, aim to provide operational efficiencies for healthcare providers and enhance patient safety by simplifying the preparation process and reducing the risk of contamination and compounding errors. They are now available for use in the U.S.
